The Irish researchers Siobhan Glavey, Catherine Duane and Michael O’Dwyer respectively from RCSI (Royal College of Surgeons, Ireland), Beaumont Hospital, Dublin and the University of Galway, explore the emerging therapeutic field of adoptive cellular therapy for multiple myeloma, with a particular emphasis on the clinical impact of these therapies for patients with high-risk myeloma.
Multiple myeloma remains a predominantly incurable disease marked by inevitable relapse and resistance to medical interventions.
The recent emergence of T cell-based agents has revolutionized the treatment landscape for individuals with relapsed and refractory multiple myeloma. Among these, chimeric antigen receptor CAR-T cell therapy has arisen as an exceedingly promising intervention, especially for those confronting refractory disease.
Find the original research review in the reference below.